Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPOs and the New FDA

This article was originally published in RPM Report

Executive Summary

Ironwood Pharmaceuticals and Anthera Pharmaceuticals tested the public offering market in early 2010. The two companies share a positive reading on a thaw in the freeze on public financings, but they show different attitudes on the nature of the regulatory climate. To Ironwood, past regualtory difficulties for other companies are an opportunity. Ironwood does not see much of a threat from new FDA safety tools. Anthera sees the threat but says it has a plan to navigate the new authorities.

You may also be interested in...



Entering the World of REMS: Entereg Sets New Standard

Entereg is the most important new drug approved by FDA so far in 2008. Not because of its commercial prospects, which are far more limited than development partners GSK and Adolor once hoped for, but because it is a precedent-setting use of the agency's new drug safety authorities-and a case study in how those new tools can save a drug that might otherwise never have been marketed at all.

Is The Opioid REMS Too Big To Study?

US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.

Growing Pains For US FDA Oversight Of Opioids: Starting Over On Assessment Of REMS

Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.

Topics

Related Companies

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel